Boehringer Ingelheim announced today a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing cutting-edge use cases for quantum computing in pharmaceutical research and development (R&D), specifically including molecular dynamics simulations. The new partnership combines Boehringer Ingelheim’s leading expertise in the field of computer-aided drug design and in silico modeling with Google’s outstanding resources as one of the leading developers of quantum computers and algorithms. Boehringer Ingelheim is the first pharmaceutical company worldwide to join forces with Google in quantum computing. The partnership is designed for three years and is co-led by the newly established Quantum Lab of Boehringer Ingelheim.
“We are really excited about joining forces with Google, the leading tech company when it comes to quantum computing,” says Michael Schmelmer, Member of the Board of Managing Directors of Boehringer Ingelheim with responsibility for Finance and Group Functions. “Quantum computing has the potential to significantly accelerate and enhance R&D processes in our industry. Quantum computing is still very much an emerging technology. However, we are convinced that this technology could help us to provide even more humans and animals with innovative and groundbreaking medicines in the future.”
The new collaboration is part of Boehringer Ingelheim’s comprehensive digital transformation strategy with the aim to better leverage and accelerate the company’s promising pipeline and ultimately bringing more medical breakthroughs to patients in need. Boehringer Ingelheim is significantly increasing its investment in a broad range of digital technologies, encompassing key areas such as Artificial Intelligence (AI), machine learning, and data science to better understand diseases, their drivers and biomarkers, and digital therapeutics.
“Extremely accurate modelling of molecular systems is widely anticipated as among the most natural and potentially transformative applications of quantum computing. Therefore, Google is excited to partner with Boehringer Ingelheim to explore use cases and methods for quantum simulations of chemistry. Boehringer Ingelheim brings both an impressive quantum computing team and deep expertise in real world applications of these capabilities in the pharmaceuticals space,” says Ryan Babbush, Head of Quantum Algorithms at Google.
Computational approaches are already a cornerstone in the design and development of innovative new medicines, making a significant contribution to improving the health of humans and animals. However, given their algorithm structure, today's computers are not able to solve many of the real complex challenges which are essential for the early stages of pharmaceutical R&D, most importantly simulating and analyzing molecules related to disease mechanisms. Quantum computing has the potential to accurately simulate and compare much larger molecules than currently possible, creating new opportunities for pharmaceutical innovation and therapies for a range of diseases.“
Researching and developing new, groundbreaking therapies for diseases with high unmet medical need is what our work at Boehringer Ingelheim is all about,” says Michel Pairet, Member of the Board of Managing Directors of Boehringer Ingelheim with responsibility for the company’s Innovation Unit. “Together with Google, our goal is to apply the use of quantum computing in biopharmaceutical R&D and thus continue to make a decisive contribution to medical progress for patients around the world.”
“The thought leadership of Boehringer Ingelheim's quantum research effort is very impressive. This is reflected in the quick turnaround time that their strong quantum research team got assembled, and their commitment to open research. We are looking forward to jointly working on the field with fundamental research and a joint vision for solving relevant pharma problems in the beyond-classical regime over the next decade,” says Markus Hoffmann, Google Quantum AI Partnerships.
Boehringer Ingelheim will invest significantly in the coming years to realize the full potential of quantum computing. The company has already set up a dedicated Quantum Lab and hired outstanding experts in the field of quantum computing from academia, industry, and quantum providers. Partnerships from Industry and Academia will complement the respective teams. Colleagues mainly from the Boehringer Ingelheim’s Innovation Unit and IT support these experts in their work.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of
19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.